PB2358: PHASE 1-2 STUDY OF THE SAFETY, PK, PD, AND PRELIMINARY ACTIVITY OF TOLINAPANT IN COMBINATION WITH ORAL DECITABINE/CEDAZURIDINE AND ORAL DECITABINE/CEDAZURIDINE ALONE IN SUBJECTS WITH R/R PTCL
Jake Shortt,
Brian Poligone,
Vincent Ribrag,
Pier Luigi Zinzani,
Dima El-Sharkawi,
Jan Walewski,
Anca Prica,
Laksmi Wilson,
Sonia Souza,
Harold Keer,
Jason Taylor,
Enrica Marchi
Affiliations
Jake Shortt
1 Monash University and Monash Health, Clayton, Victoria, Australia
Brian Poligone
2 Rochester Skin Lymphoma Medical Group, PLLC, Fairport, United States
Vincent Ribrag
3 Institute of Hematology “Seràgnoli” University of Bologna Italy, Villejuif, France
Pier Luigi Zinzani
4 Institute of Hematology “Seràgnoli”, University of Bologna, Bologna, Italy
Dima El-Sharkawi
5 The Royal Marsden NHS Foundation Trust, Surrey, United Kingdom
Jan Walewski
6 Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy, Warszawa, Poland
Anca Prica
7 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Laksmi Wilson
8 Astex Pharmaceuticals, Inc., Pleasanton, United States
Sonia Souza
8 Astex Pharmaceuticals, Inc., Pleasanton, United States
Harold Keer
8 Astex Pharmaceuticals, Inc., Pleasanton, United States
Jason Taylor
8 Astex Pharmaceuticals, Inc., Pleasanton, United States
Enrica Marchi
9 Emily Couric Clinical Cancer Center, University of Virginia, Charlottsville, United States
